tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), BioMarin Pharmaceutical (BMRN) and Enovis (ENOV)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arbutus Biopharma (ABUSResearch Report), BioMarin Pharmaceutical (BMRNResearch Report) and Enovis (ENOVResearch Report).

Arbutus Biopharma (ABUS)

In a report issued on August 4, Brian Skorney from Robert W. Baird maintained a Hold rating on Arbutus Biopharma, with a price target of $4.00. The company’s shares closed last Thursday at $2.47, close to its 52-week low of $1.93.

According to TipRanks.com, Skorney has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.9% and a 45.3% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Enanta Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Arbutus Biopharma is a Strong Buy with an average price target of $6.63.

See Insiders’ Hot Stocks on TipRanks >>

BioMarin Pharmaceutical (BMRN)

In a report issued on August 4, Joel Beatty from Robert W. Baird maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $112.00. The company’s shares closed last Thursday at $95.07, close to its 52-week high of $97.76.

According to TipRanks.com, Beatty is a 4-star analyst with an average return of 6.2% and a 51.9% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and Syndax Pharmaceuticals.

BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $110.00, which is a 15.0% upside from current levels. In a report issued on August 1, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $140.00 price target.

Enovis (ENOV)

Robert W. Baird analyst Jeff Johnson maintained a Buy rating on Enovis on August 4 and set a price target of $73.00. The company’s shares closed last Thursday at $58.56.

According to TipRanks.com, Johnson is a 5-star analyst with an average return of 18.7% and a 55.2% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Tandem Diabetes Care, and Patterson Companies.

Currently, the analyst consensus on Enovis is a Moderate Buy with an average price target of $67.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABUS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More